HomeUSAForesite Capital Closes Sixth Fund, at $900M

Foresite Capital Closes Sixth Fund, at $900M

Foresite Capital, a SanFrancisco, CA-based multi-stage healthcare and life sciences investment firm, closed its sixth fund, at $900M.

Limited partners include a broad range of investors, among them university endowments, charitable foundations, medical institutions, pension funds, insurance companies, private banks and family offices worldwide.

Fund VI is investing in growth-oriented companies in three main areas: precision therapeutics, life science infrastructure, and healthcare delivery. Backed companies include Alumis, Latigo, CG Oncology,  RayThera, and Xaira Therapeutics.

Led by Jim Tananbaum, founder and CEO, Foresite Capital is a multi-stage healthcare and life sciences investment firm with more than $3.5 Billion in assets under management. The firm aims to address areas of unmet medical need by funding promising healthcare and life sciences businesses at all stages of their life cycles.

Since its establishment in 2011, Foresite has adhered to a data and science-driven investment strategy, resulting in more than 47 IPOs, 28 mergers and acquisitions and the approval of 58 drugs by the FDA. The team offers comprehensive support to its portfolio companies, leveraging expertise in company formation, therapeutics product development, and data science / machine learning to provide strategic guidance and technical assistance.